Last updated: September 27, 2026
Felodipine is a generic, immediate-release-free antihypertensive supplied primarily as an extended-release tablet. Its commercial opportunity is not based on new-molecule exclusivity. It depends on reliable controlled release, improved dissolution of a poorly water-soluble active pharmaceutical ingredient, manufacturing efficiency, differentiated dosage forms, and supply-chain economics.
The strongest formulation priorities are:
- Maintain a reproducible extended-release profile over the labeled 24-hour dosing interval.
- Improve wetting and dissolution without creating dose dumping.
- Control particle size, polymorphic form, and content uniformity.
- Use excipients with established regulatory histories and broad global availability.
- Avoid unnecessary formulation complexity because felodipine is already a mature, low-price generic.
What is felodipine and how is it regulated?
Felodipine is a dihydropyridine calcium-channel blocker indicated for the treatment of hypertension. The U.S. product is an extended-release tablet generally administered once daily. The reference product is Plendil, originally developed by AstraZeneca and approved under U.S. New Drug Application 19-834. The active ingredient is felodipine, chemically a highly lipophilic 1,4-dihydropyridine derivative.
| Attribute |
Felodipine |
| Therapeutic class |
Dihydropyridine calcium-channel blocker |
| Main indication |
Hypertension |
| Common dosage strengths |
2.5 mg, 5 mg, and 10 mg extended-release tablets |
| U.S. reference product |
Plendil |
| Dosage form |
Extended-release oral tablet |
| Regulatory pathway for generics |
ANDA, subject to pharmaceutical equivalence and bioequivalence |
| Biologic status |
Not a biologic; biosimilar pathway does not apply |
| Solubility profile |
Very slightly soluble or practically insoluble in water |
| Key metabolic pathway |
CYP3A4 |
| Major food interaction |
Grapefruit and grapefruit juice can increase exposure |
| Current market structure |
Generic-dominated |
FDA labeling states that felodipine is extensively metabolized by CYP3A4 and that exposure can increase with strong CYP3A4 inhibitors or grapefruit products. The drug is also associated with dose-related peripheral edema and gingival hyperplasia, which limits the commercial value of simply increasing systemic exposure.[1]
What excipient properties are most important for felodipine?
Felodipine requires excipient selection that addresses two competing objectives: increasing apparent dissolution of a lipophilic drug and preserving controlled release.
The drug’s low aqueous solubility can produce dissolution sensitivity to particle size, wetting, compression force, tablet porosity, and gastrointestinal conditions. The formulation must also prevent rapid liberation of felodipine from the extended-release matrix.
Target excipient functions
| Formulation function |
Suitable excipient classes |
Commercial rationale |
| Hydrophilic release matrix |
Hypromellose, hydroxypropyl cellulose |
Established technology; scalable; compatible with once-daily tablets |
| Dilution and compressibility |
Microcrystalline cellulose, lactose monohydrate |
Supports direct compression and tablet robustness |
| Wetting and dissolution support |
Surfactants, selected polymers, colloidal silicon dioxide |
Can improve drug dispersion and reduce dissolution variability |
| Lubrication |
Magnesium stearate, sodium stearyl fumarate |
Supports tooling and ejection |
| Flow improvement |
Colloidal silicon dioxide |
Helps manage low-dose content uniformity |
| Taste and light protection |
Film-coating polymers, titanium dioxide, iron oxides |
Supports stability and product identification |
| Chemical stabilization |
Antioxidant or oxygen-control strategy where justified |
Relevant because dihydropyridines can be oxidation-sensitive |
The reference formulation has historically used a combination of hydrophilic polymers, lactose, microcrystalline cellulose, magnesium stearate, silicon-containing flow aids, and film-coating ingredients. Exact excipient composition varies by manufacturer and market.[1,2]
How should an extended-release felodipine tablet be designed?
The most defensible commercial platform is a hydrophilic matrix tablet with controlled hydration and erosion. A matrix approach avoids the manufacturing complexity of multiparticulate capsules or osmotic systems while preserving a familiar generic dosage form.
Hydrophilic matrix strategy
Hypromellose is the leading candidate for the primary release-controlling polymer. Higher-viscosity grades generally slow hydration and drug diffusion, while lower-viscosity grades can support faster release and easier processing. Polymer loading, particle size, compression force, and tablet geometry must be optimized together.
A development program should evaluate:
- Hypromellose viscosity grade and concentration.
- Felodipine particle-size distribution.
- Drug-to-polymer ratio.
- Lactose-to-microcrystalline-cellulose ratio.
- Tablet hardness and porosity.
- Magnesium stearate concentration and blending time.
- Dissolution after exposure to different pH conditions.
- Alcohol sensitivity and agitation sensitivity.
- Stability under heat and humidity.
The main technical risk is an extended-release profile that passes a single dissolution condition but changes materially with pH, agitation, food, or manufacturing scale.
Multiparticulate and coated-pellet strategy
Felodipine can also be developed as coated pellets or granules filled into capsules or compressed into tablets. This approach can improve dose distribution and reduce sensitivity to local tablet defects. It usually increases process steps, coating controls, and cost.
Multiparticulates may be commercially attractive when the target market values:
- Lower variability across gastrointestinal conditions.
- Flexible dose combinations.
- Pediatric or geriatric administration.
- Capsule-based products.
- More sophisticated lifecycle-management claims.
For a low-price hypertension product, the added cost is difficult to justify unless the product obtains a meaningful regulatory or clinical advantage.
Amorphous and lipid-based strategies
Amorphous solid dispersions, surfactant-assisted formulations, and lipid-based systems can increase dissolution. Their commercial usefulness is limited by physical stability, recrystallization risk, excipient load, and scale-up complexity.
These technologies are more suitable for:
- A differentiated low-dose product.
- A fixed-dose combination.
- A product targeting lower variability.
- A reformulation supported by pharmacokinetic or food-effect data.
- A branded generic with a documented adherence or tolerability benefit.
They are less attractive for a conventional ANDA that competes mainly on price.
What formulations are protected by felodipine patents?
Felodipine’s original compound and reference-product formulation rights are mature. The principal commercial protection for conventional felodipine extended-release tablets has expired, leaving the market open to generic competition.
Patent and exclusivity position
| Protection category |
Current commercial relevance |
| Original compound patent |
Expired |
| Original extended-release formulation protection |
Expired or no longer a practical barrier to standard generic entry |
| FDA new chemical entity exclusivity |
Expired |
| Pediatric exclusivity |
No current market-blocking relevance |
| Orange Book patent barrier |
No known current barrier preventing conventional generic competition |
| New formulation patents |
Possible for genuinely distinct technologies, but they would not automatically block existing generic tablets |
| Method-of-use patents |
Limited commercial leverage unless tied to a narrow, enforceable indication |
| Biosimilar exclusivity |
Not applicable |
The FDA Orange Book remains the controlling source for current U.S. patent listings and regulatory exclusivity. Applicants must review the current listing for NDA 19-834 and any relevant approved supplemental applications before filing or launching.[3]
A new patent on a coating process, particle-size range, polymer ratio, or dissolution profile would need meaningful technical differentiation and enforceable claim scope. A patent that covers only routine excipient substitutions would have limited value against established generic products.
When does felodipine lose exclusivity?
Felodipine lost practical small-molecule exclusivity years ago. Generic products entered the U.S. market after expiry of the original product and formulation protections. The market therefore does not depend on a future loss-of-exclusivity event.
The relevant commercial question is not when felodipine loses exclusivity. It is whether a manufacturer can achieve adequate gross margin in a mature generic market.
U.S. regulatory milestones
| Event |
Status |
| Original FDA approval |
Historical approval of Plendil under NDA 19-834 |
| Generic approval route |
ANDA |
| Reference product |
Plendil extended-release tablets |
| Current market access |
Generic competition |
| Current biosimilar exposure |
None |
| Current Paragraph IV opportunity |
Limited because the core product is already off-patent |
| Current 180-day first-filer value |
Potentially limited and dependent on any remaining listed patent or exclusivity rights |
What is the Orange Book status of felodipine?
Felodipine is an Orange Book-listed small molecule with an established reference product and multiple generic versions. Orange Book review should focus on:
- NDA 19-834 and its approved supplements.
- Whether any patent is listed against a specific strength or dosage form.
- Whether any listed patent has expired.
- Whether a generic applicant must submit a Paragraph IV certification.
- Whether any product-specific exclusivity remains.
For a conventional extended-release tablet, the absence of an active market-blocking patent means the principal regulatory hurdle is bioequivalence rather than patent clearance.
Paragraph IV challenges
Paragraph IV litigation is most commercially relevant when an ANDA applicant seeks to launch before listed patent expiry. For legacy felodipine products, the economic value of a new Paragraph IV strategy is likely lower than for a branded product with a large remaining market.
A Paragraph IV filing could still matter if:
- A newly listed formulation patent covers a commercially important product.
- A generic applicant develops a materially different release technology.
- A first-filer position creates temporary market exclusivity.
- A branded-generic sponsor obtains a new patent on a distinct formulation or use.
No major current Paragraph IV controversy is central to the conventional felodipine market based on the mature generic status of the product.
How strong is the felodipine patent estate?
The conventional felodipine patent estate is weak from a blocking perspective but potentially useful for incremental innovation.
Stronger patent opportunities
The most defensible new patent claims would relate to:
- A specific controlled-release architecture.
- A validated particle-size or polymorph combination.
- A composition that reduces food-effect variability.
- A stable amorphous dispersion with defined solid-state properties.
- A manufacturing process that produces a narrow dissolution profile.
- A fixed-dose combination with a non-obvious compatibility solution.
- A novel dosage form that improves swallowing or administration.
Weaker patent opportunities
Claims are less likely to create durable value when they cover:
- Routine use of lactose or microcrystalline cellulose.
- Generic substitution of one lubricant for another.
- Broad claims to a standard hypromellose matrix.
- Conventional film coating.
- A narrow excipient concentration without demonstrated performance.
- A dissolution range that is readily achieved by existing products.
Patent strength depends on unexpected technical results, freedom to operate, claim breadth, and the ability to detect infringement through product testing or regulatory records.
Which excipient strategies create commercial opportunities?
The best opportunities are formulation-led rather than molecule-led.
1. Low-cost, high-reliability generic
This strategy uses widely available excipients, direct compression or dry granulation, and a conventional hydrophilic matrix. Its commercial advantage is manufacturing cost, supply continuity, and low regulatory risk.
Priority excipients include:
- Hypromellose.
- Microcrystalline cellulose.
- Lactose monohydrate.
- Colloidal silicon dioxide.
- Magnesium stearate.
- Standard film-coating polymers.
This is the most practical strategy for tenders, pharmacy-channel supply, and markets where price dominates.
2. Improved dissolution formulation
A wetting agent or dispersion aid can address low solubility and reduce batch-to-batch dissolution variability. The formulation must preserve the extended-release profile and avoid an excessive early-release peak.
Potential commercial claims include improved robustness across pH, lower dissolution variability, or reduced sensitivity to manufacturing conditions. These claims require comparative dissolution and pharmacokinetic evidence.
3. Fixed-dose combination product
Felodipine can be paired with other antihypertensive agents, including angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or diuretics. The opportunity depends on market demand, clinical rationale, and the ability to manage chemical and physical compatibility.
The principal challenges are:
- Different release requirements.
- Dose-ratio constraints.
- Chemical interaction during storage.
- Larger tablet size.
- Separate bioequivalence obligations.
- Potentially crowded patent positions around the partner drug.
4. Patient-friendly dosage form
Orally disintegrating, sprinkle, or mini-tablet formats could target patients with swallowing difficulty. The central formulation challenge is maintaining extended release after dispersion or disintegration.
A simple immediate-release orally disintegrating tablet would not be equivalent to the established once-daily extended-release product without a new clinical and regulatory strategy.
5. Regional supply and dual-sourcing platform
Felodipine is suitable for a multi-market excipient platform because the core excipient set is globally familiar. Manufacturers can reduce supply risk by qualifying multiple grades of hypromellose, lactose, and microcrystalline cellulose.
The regulatory burden is lower when the alternate excipient remains within established compendial specifications and the finished product continues to meet approved quality and bioequivalence requirements.
What manufacturing and IP barriers affect felodipine?
The largest barriers are technical consistency and economics, not basic access to the active ingredient.
| Barrier |
Impact |
| Low drug solubility |
Can create dissolution and bioequivalence variability |
| Low dose strength |
Raises content-uniformity risk |
| Extended-release requirement |
Increases formulation and dissolution testing burden |
| Polymer grade variability |
Can shift release kinetics |
| Lubrication sensitivity |
May reduce tablet wetting and alter release |
| Particle-size variation |
Can change dissolution and blend uniformity |
| Limited market price |
Constrains investment in complex technologies |
| API supplier concentration |
Can create quality and continuity risk |
| Legacy formulation knowledge |
Gives established manufacturers a process advantage |
| Patent overhang from new formulations |
May affect differentiated products |
Manufacturers should control API particle size, polymorphic form, assay, impurities, residual solvents, and specific surface area. Vendor qualification should include change-notification obligations because even compendial excipient changes can alter release behavior.
How does felodipine compare with other calcium-channel blockers?
Felodipine competes with amlodipine, nifedipine, lercanidipine, and other antihypertensive agents. Amlodipine has a strong commercial advantage from simple once-daily immediate-release tablet manufacturing and broad generic availability. Nifedipine has a larger range of modified-release technologies and a more established formulation-development history.
| Product |
Formulation burden |
Generic competition |
Commercial implication |
| Felodipine ER |
Moderate to high |
High |
Requires release-control expertise |
| Amlodipine |
Low |
Very high |
Lower manufacturing cost; intense price pressure |
| Nifedipine ER |
High |
High |
More formulation differentiation but more technical complexity |
| Lercanidipine |
Moderate |
Market-dependent |
Opportunity varies by jurisdiction |
| Verapamil ER |
High |
High |
More complex release and interaction profile |
Felodipine can compete where suppliers have reliable ER manufacturing and where local procurement values product continuity. It is less attractive as a purely lowest-cost product than amlodipine.
What is the revenue exposure and commercial outlook?
Felodipine is unlikely to support major revenue from exclusivity pricing. Revenue depends on volume, tender access, geographic coverage, and manufacturing cost.
The strongest commercial models are:
- High-volume generic supply.
- Private-label or contract-manufactured extended-release tablets.
- Regional licensing of approved generic products.
- Fixed-dose combinations.
- Branded generics with a clinically supported formulation advantage.
- Contract development and manufacturing for companies lacking ER capabilities.
A new formulation should be screened against three commercial tests:
- Can it achieve a measurable reduction in dissolution or bioequivalence risk?
- Can the added manufacturing cost be recovered in the target market?
- Can the formulation obtain differentiated regulatory, patent, or contracting value?
If the answer to all three is no, a conventional matrix tablet is the better investment.
What litigation and settlement risks affect felodipine?
The major branded-product patent litigation cycle is historical rather than an active market driver. Current litigation risk is more likely to arise from:
- Process patents on specialized formulations.
- Trade-secret disputes involving release-control manufacturing.
- API supply and quality claims.
- ANDA litigation tied to a newly listed formulation patent.
- Contract disputes between licensors, distributors, and manufacturers.
Settlement agreements are unlikely to materially alter access to the conventional felodipine market unless a new formulation patent is listed and commercially relevant. A standard generic entrant should prioritize freedom-to-operate review of any current product-specific patent listing rather than relying on legacy Plendil litigation history.
Key Takeaways
- Felodipine is a mature, generic small-molecule antihypertensive with no biosimilar issue.
- The main product is an extended-release tablet, making polymer selection and dissolution control central to development.
- Hypromellose, lactose, microcrystalline cellulose, silicon dioxide, and magnesium stearate provide a practical baseline excipient system.
- The original compound and conventional product protections are expired or no longer commercially blocking.
- Current value lies in manufacturing efficiency, reliable bioequivalence, fixed-dose combinations, patient-friendly dosage forms, and regional supply.
- New patent value is strongest for demonstrably improved release, stability, solid-state control, or administration.
- A conventional low-cost generic has the lowest regulatory risk but faces intense price competition.
- Complex formulation technologies are commercially justified only when they produce measurable clinical, regulatory, supply-chain, or contracting advantages.
FAQs
Is felodipine a BCS Class II drug?
Felodipine is generally treated as a poorly water-soluble, highly permeable compound, consistent with a BCS Class II development profile. Exact biowaiver treatment depends on the applicable jurisdiction and product-specific regulatory requirements.
Which excipient is most important for felodipine extended release?
Hypromellose is typically the most important release-controlling excipient in a hydrophilic matrix system. Its viscosity grade, concentration, hydration behavior, and interaction with tablet porosity directly affect drug release.
Can felodipine be formulated as an immediate-release tablet?
It can be formulated as an immediate-release product, but that product would not automatically be substitutable for the established once-daily extended-release formulation. A separate regulatory and clinical strategy would be required.
Does felodipine have biosimilar competition?
No. Felodipine is a chemically synthesized small molecule. Competition occurs through generic drug applications, not biosimilar applications.
Is a fixed-dose felodipine combination commercially attractive?
It can be attractive in markets that value combination antihypertensive therapy, but success depends on partner-drug selection, tablet size, compatibility, bioequivalence, pricing, and any remaining patents covering the combination or companion product.
References
-
U.S. Food and Drug Administration. (2024). Felodipine extended-release tablets: Prescribing information. FDA/DailyMed labeling database.
-
National Library of Medicine. (2024). DailyMed: Felodipine extended-release tablet labels. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Guidance for Industry.
-
U.S. Food and Drug Administration. (2017). Dissolution testing and specification criteria for oral immediate-release solid dosage forms containing highly soluble drug substances. Guidance for Industry.
